Journal of the American College of Cardiology 2025; 85(27 May 2025): 1959-70 |
Witteles, Ronald M. et al.
Patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have high mortality and morbidity. Vutrisiran, a subcutaneous RNA interference therapeutic, reduced the composite of all-cause mortality...
Amyloid 2025; 32(2): 139-44 |
Hironobu
Naiki
et al.
Accurate tissue typing in amyloidosis is essential to provide appropriate therapy for individual patients. To get a real-life overview of typing strategies worldwide. The International Society of Amyloidosis...
Journal of neurology 2025 Apr; 272(5): 340 |
Manco Carlo et al.
Hereditary transthyretin amyloidosis (ATTRv) is a rare disorder caused by pathogenic TTR gene variants. Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are potential biomarkers...
By requesting access to the "ATTR Expert" service, I agree that GNM Healthcare Consulting France SAS may use the data acquired during my access request to provide me with twice per month
information related to its services in accordance with the
Privacy Policy.
You have the right to access, rectify and delete your data, which you can exercise by sending your request to
dpo@gnmhealthcare.com.
You can exercise your right to object by requesting the deletion of your data at any time by clicking on the "Delete my data" link.
